Managing Patients With Type 2 Diabetes Poses Challenges - Pharmacy Times

 
 
Managing Patients With Type 2 Diabetes Poses ChallengesPharmacy TimesHealth care providers should individualize therapy to achieve the best possible outcomes.
 
Related NewsFeeds

How understanding organ growth in fruit flies sheds light on genetic diseasesFierceBiotechRutgers University scientists have made a surprising discovery about how wings form in fruit flies, disrupti

0 visits

Virginia Retirement Systems ET AL Boosts Position in Alexion Pharmaceuticals, Inc. (ALXN)Fairfield CurrentVirginia Retirement Systems ET AL boosted its holdings in Alexion Pharmaceuticals, Inc. (NAS

0 visits

Hot Stock In The Spotlight : - AcelRx Pharmaceuticals, Inc., (NASDAQ: ACRX)Nyse NewsTodayThe Relative Strength Index (RSI) is a technical indicator used in the analysis of financial markets. It is i

0 visits

Systemic Lupus Erythematosus Market Size Worth Around USD 2.7 billion by 2026: Acumen Research and Consulting - Press ReleaseDigital JournalAcumen Research and Consulting, a global provider of marke

0 visits

Can A Similar Series of Events Expected At Infinity Pharmaceuticals, Inc. (INFI), SM Energy Company (SM)Post AnalystInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) enjoyed a weak run from the open in t

0 visits

Traders Brace for Comeback of Volatility: Amneal Pharmaceuticals, Inc. (AMRX), II-VI Incorporated (IIVI)Post AnalystWednesday seemed like a heavier volume day for Amneal Pharmaceuticals, Inc. (NYSE:

0 visits

Alteration Today: - AVEO Pharmaceuticals, Inc., (NASDAQ: AVEO)Nyse NewsTodayThe Relative Strength Index (RSI) is a technical indicator used in the analysis of financial markets. It is intended to ch

0 visits

Continuous Glucose Monitoring (CGM) Systems/Devices Market Size Worth Around $2.2 billion by 2026: Acumen Research and ConsultingGlobeNewswireAcumen Research and Consulting, a global provider of mar

0 visits

M&T Bank Corp Boosts Holdings in Alnylam Pharmaceuticals, Inc. (ALNY)Fairfield CurrentM&T Bank Corp boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.7% during the f

0 visits

Nov 12, 2018 4:57 AM ET Diabetes Injection Pens Market: Global Key Players, Trends, Share, Industry Size, Growth, Opportunities, Forecast To 2023Honest BusinessmanWiseGuyReports.com adds "Diabetes I

0 visits

iShares US Pharmaceuticals ETF (IHE) Position Cut by Karp Capital Management CorpFairfield CurrentKarp Capital Management Corp cut its position in shares of iShares US Pharmaceuticals ETF (NYSEARCA:

0 visits

Kala Pharmaceuticals (KALA) Upgraded by BidaskClub to "Buy?Fairfield CurrentBidaskClub upgraded shares of Kala Pharmaceuticals (NASDAQ:KALA) from a hold rating to a buy rating in a research note pub

0 visits

Early Signs of DiabetesU.S. News & World ReportFrequent urination, extreme thirst and dental problems could be early signs of diabetes.

0 visits

China Biologic Products Holdings (CBPO) Stock Moves with change of 0.41%News LeadingInvestors tracking shares of China Biologic Products Holdings (CBPO) may be focusing on where the stock is trading

0 visits

Merck to acquire Immune DesignIn-PharmaTechnologist.comAnnounced today, the deal sees Merck pay $5.85 per share to acquire Immune Design and its portfolio of late-stage immunotherapies. Immune Desig

0 visits

Inflammatory Bowel Disease (IBD) Treatment Market Revenue To Witness Steady Growth Through 2017-2025Honest VersionInflammatory Bowel Disease (IBD) Treatment Market (Drug Class - TNF Inhibitors, Amin

0 visits

Radio-tracking dolphins reveals intimate details about their behaviorEurekAlertThe most extensive radio-tracking effort of bottlenose dolphins in the Indian River Lagoon using radio-telemetry reveal

0 visits

Catalyst Pharmaceuticals Responds to Letter from Senator Bernie SandersGlobeNewswireCORAL GABLES, Fla., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a

0 visits

Sartorius successfully closes fiscal year 2018 and plans to continuously expandNews-Medical.netSartorius, a leading international partner of biopharmaceutical research and the industry, confirmed it

0 visits

Alnylam As A Strategic InvestmentSeeking AlphaAlnylam is a leader in RNA therapy, specifically RNAi. Alnylam generated significant income from Onpattro in Q4. The platform and deep pipeline are more

0 visits

 
weSRCH App on Apple